EP1802604A1 - 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt - Google Patents

1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt

Info

Publication number
EP1802604A1
EP1802604A1 EP05792250A EP05792250A EP1802604A1 EP 1802604 A1 EP1802604 A1 EP 1802604A1 EP 05792250 A EP05792250 A EP 05792250A EP 05792250 A EP05792250 A EP 05792250A EP 1802604 A1 EP1802604 A1 EP 1802604A1
Authority
EP
European Patent Office
Prior art keywords
piperidin
quinolin
benzyl
methyl
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05792250A
Other languages
German (de)
French (fr)
Inventor
Stephane Redey
Stephan Buchmann
Jean Michel Bonard
Bertrand Woinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to EP05792250A priority Critical patent/EP1802604A1/en
Priority claimed from PCT/IB2005/053340 external-priority patent/WO2006040728A1/en
Publication of EP1802604A1 publication Critical patent/EP1802604A1/en
Withdrawn legal-status Critical Current

Links

Definitions

  • the present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea as crystalline, stoichiometrically defined and non- hygroscopic sulfate salt and a process for its preparation. Further, the present invention relates to the use of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea as crystalline, stoichiometrically defined and non- hygroscopic sulfate salt alone or in combination with other compounds.
  • the present invention also relates to compositions containing said 1-[2-(4-benzyl- 4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline, stoichiometrically defined and non-hygroscopic sulfate salt and inert carrier material which are useful as urotensin-ll antagonist.
  • An object of the present invention is to provide 1-[2-(4-benzyl-4-hydroxy-piperidin- 1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I in a stoichiometrically defined and non-hygroscopic crystalline form which shows improved properties suitable for a pharmaceutical product, pharmaceutical preparations, production in large scale and storage.
  • the present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea of formula I as a sulfate trihydrate.
  • a sulfate salt of 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I is described by [Martine Clozel et. al., J Pharmacol Exp Ther. 2004; DOI:10.1124/jpet.104.068320] but no procedure for its preparation has been disclosed.
  • the present invention also relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as a sulfate dihydrate.
  • the present invention also relates to a process for preparing 1-[2-(4-benzyl- 4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as stoichiometrically defined and non-hygroscopic sulfate salt which process comprises
  • 3-(2-methyl-quinolin-4-yl)-urea sulfate hydrate by stirring in water, in a mixture of water and an organic solvent, or by exposure to an atmosphere of controlled relative humidity.
  • the sulfate salt of 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I is 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin- 4-yl)-urea sulfate trihydrate.
  • the present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as stoichiometrically defined and non-hygroscopic sulfate salt obtainable by the process mentioned above.
  • compositions comprising 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as stoichiometrically defined and non-hygroscopic sulfate salt as mentioned above and inert carrier material
  • the present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as mentioned above and their use as medicaments.
  • 1-[2-(4-benzyl- 4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as described above can be used for treatment of diseases which are associated with an increase in vasoconstriction, proliferation or other disease states associated with the actions of urotensin II.
  • diseases are hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, asthma, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, or pulmonary fibrosis.
  • They can also be used for prevention of restenosis after balloon or stent angioplasty, for the treatment of cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addictions, schizophrenia, Alzheimer's disease, anxiety, obsessive-compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, neurodegenerative diseases, as well as other diseases related to a dysregulation of urotensin Il or urotensin Il receptors.
  • compositions may be administered in enteral or oral form e.g. as tablets, dragees, gelatine capsules, emulsions, solutions or suspensions, in nasal form like sprays and aerosols, or rectally in form of suppositories.
  • enteral or oral form e.g. as tablets, dragees, gelatine capsules, emulsions, solutions or suspensions, in nasal form like sprays and aerosols, or rectally in form of suppositories.
  • 1-[2-(4-Benzyl-4-hydroxy- piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as mentioned above may also be administered in intramuscular, parenteral or intravenous form, e.g. in form of injectable solutions.
  • compositions may contain 1-[2-(4-benzyl-4-hydroxy- piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as mentioned above in combination with inorganic and/or organic excipients, which are usual in the pharmaceutical industry, like lactose, maize or derivatives thereof, talcum, stearic acid or salts of these materials.
  • vegetable oils, waxes, fats, liquid or half-liquid polyols etc. may be used.
  • solutions and sirups e.g. water, polyols, saccharose, glucose etc. are used.
  • injectables are prepared by using e.g. water, polyols, alcohols, glycerin, vegetable oils, lecithin, liposomes etc.
  • Suppositories are prepared by using natural or hydrogenated oils, waxes, fatty acids (fats), liquid or half-liquid polyols etc.
  • compositions may contain in addition preservatives, stabilisation improving substances, viscosity improving or regulating substances, solubility improving substances, sweeteners, dyes, taste improving compounds, salts to change the osmotic pressure, buffer, anti-oxidants etc.
  • ⁇ - and ⁇ -blockers like phentolamine, phenoxybenzamine, atenolol, propranolol, timolol, metoprolol, carteolol, carvedilol, etc.; with vasodilators like hydralazine, minoxidil, diazoxide, flosequinan, etc.; with calcium-antagonists like diltiazem, nicardipine, nimodipine, verapamil, nifedipine, etc.; with angiotensin converting enzyme-inhibitors like cilazapril, captopril, enalapril, lisinopril etc.; with potassium channel activators like pinacidil, chromakalim, etc.; with angiotensin receptor antagonists like losartan, valsartan, candesartan, irbesartan, eprosartan, telmisartan,
  • the dosage may vary within wide limits but should be adapted to the specific situation.
  • the dosage given daily in oral form should be between about 3 mg and about 3 g, preferably between about 5 mg and about 1 g, especially preferred between 10 mg and 300 mg, per adult with a body weight of about 70 kg.
  • the dosage should be administered preferably in 1 to 3 doses of equal weight per day. As usual children should receive lower doses which are adapted to body weight and age.
  • the present invention also relates to compositions containing amorphous parts of
  • crystal or crystalline is used to describe the part of crystalline material compared to amorphous material and is estimated eg. by the line shape and the background intensity in X-ray diffraction patterns.
  • a crystallinity of 90% to 100% is estimated.
  • the crystallinity is within the range of 92 % to 100 %.
  • the crystallinity is within the range of 95 % to 100 %.
  • organic solvents means solvents or mixtures of solvents, such as Ci -4 -alkanol (CH 3 OH, C 2 H 5 OH, n-C 3 H 7 OH, 1-C 3 H 7 OH, n-C 4 H 9 OH, J-C 4 H 9 OH, t-C 4 H 9 OH), ketones (acetone, ethylmethylketone, methylisobutylketone), ethers (diethylether, tetrahydrofurane, 1 ,4-dioxane, methyl- tert. butylether) or acetonitrile.
  • Ci -4 -alkanol CH 3 OH, C 2 H 5 OH, n-C 3 H 7 OH, 1-C 3 H 7 OH, n-C 4 H 9 OH, J-C 4 H 9 OH, t-C 4 H 9 OH
  • ketones acetone, ethylmethylketone, methylisobutyl
  • organic solvents are CH 3 OH, C 2 H 5 OH, n-CsHyOH, J-CaH 7 OH and acetone. Most preferred "organic solvents” are CH 3 OH, C 2 H 5 OH, J-C 3 H 7 OH and acetone.
  • solution of sulfuric acid means solutions of sulfuric acid in water, or a solution of sulfuric acid in a mixture of water and an organic solvent., preferably aqueous solutions.
  • Sulfuric acid solutions are in the concentration range of 0.01 to 10 mol/L, more preferred in the concentration range of 0.1 to 5 mol/L, most preferred in the concentration range of 0.2 to
  • crystalline form means crystalline compounds as described before that contain 1 [2 (4 benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of Formula I, sulfuric acid and water in a defined molecular ratio X:Y:Z, whereby X and Y represent 1 , and Z represents the numbers 0 to 4. In a more preferred embodiment Z represents the numbers 0 to 3. In the most preferred embodiment Z represents the numbers 2 or 3.
  • X-ray diffraction patterns were recorded on a Bruker D5000, using a Cu- Kaip h a (1.5418 A) source, a 4OkV - 3OmA generator, in a range of 3 et 40° (2theta).
  • DVS is performed as gravimetric measurement (10 - 30 mg of sample), at a given temperature, under controlled relative humidity. Measurements are performed on a
  • SMS Surface Measurement Sytems
  • RH relative humidity
  • Figure 1 shows the XRD-diffraction pattern of the compound described in Example 1.
  • Table 1 summarizes the peaks and their intensity.
  • Example 1 Type 2Th/Th locked - Start : 3.000° - End : 40.000° - Step : 0.020° - Step time : 1 s - Temp. : 25°C (room temperature) - Time Started : 3 s - 2-Theta : 3.000° - Theta : 1.500° - Phi : 0.00° DIF - Y : 77.31 % - d x by : 1.- WL : 1.54056 - 0-
  • Table 2 summarizes the results of two cycles (0 to 85 % relative humidity) in a DVS measurement (4O 0 C) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate described in Example 1.
  • Table 2 DVS data of the compound described in Example 1
  • the formed precipitate is filtered, washed with cooled CH 3 OH (- 5°C, 54 L) and dried under a stream of nitrogen provide 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I sulfate as a non-defined hydrate.
  • a slurry of the so obtained salt in H 2 O (16.2% w/w) is stirred for 3 days at 25°C. Filtration and drying at 30 0 C under a wet stream of nitrogen (50% RH) provides the title compound.
  • Figure 2 shows the XRD-diffraction pattern of the compound described in Example 2.
  • Table 3 summarizes the peaks and their intensity.
  • Example 2 Type 2Th/Th locked - Start : 3.000° - End : 40.000° - Step : 0.020° - Step time : 1 s - Temp. : 30°C - Time Started : 3 s - 2-Theta : 3.000° - Theta : 1.500° - Phi : 0.00° - Aux1 : 0.0 DIF - Y : 77.08 % - d x by : 1.- WL : 1.54056 - 0-
  • Table 4 summarizes the results of three cycles (0 to 85 % relative humidity) in a DVS measurement (25°C) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate described in Example 2.
  • the formed precipitate is filtered, washed with cooled CH 3 OH (- 5°C, 54 L) and dried under a stream of nitrogen provide 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I sulfate as a non-defined hydrate.
  • the so obtained salt is exposed to humid atmosphere (>70 % RH) at 25 0 C to provide the title compound.
  • Figure 3 shows the XRD-diffraction pattern of the compound described in Example 3.
  • Table 5 summarizes the peaks and their intensity.
  • Example 3 Type 2Th/Th locked - Start : 4.010° - End : 40.010° - Step : 0.020° - Step time : 1 s - Temp. : 25 0 C (room temperature) - Time Started : 0 s - 2-Theta : 4.010° DIF - Y : 79.17 % - d x by : 1.- WL : 1.54056 - 0-
  • the wet seed used in the above procedure is prepared by mixing 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea sulfate trihydrate (Example 1 , 104 g) with a saturated solution (421 g) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea sulfate trihydrate (Example 1 , 73.9 g) in aqueous ethanol (50 % VWW, 81O g).
  • the obtained mixture is maintained at 50 0 C for about 15 minutes, then it is cooled to 0 0 C with a cooling rate of 15°C/h and maintained at this temperature for least 1 hour before filtration and washing with aqueous ethanol (50 % W/W, 3 kg).
  • the solid is dried in a conductive agitated dryer at a temperature of 35 ⁇ 3°C under a wet stream of nitrogen (45+5% RH), optionally under stirring (max. 70 rpm) in case the cake humidity is below 25%, to provide the title compound with a purity of 99.8% with a yield of approximately 94%.
  • the wet seed used in the above procedure is added in two shots and is prepared by mixing 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate (Example 1 , 6.5 g) with a saturated solution (13.9 g for the first shot, plus 15.6 g for subsequent rinsing and second shot) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate (Example 1 , 7.0 g) in aqueous ethanol (50 % W/W, 50.0 g) for about 2 minutes.
  • the first shot of wet seed is prepared at least 5 minutes before use to ensure that the seed is correctly wetted.

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl­-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt and a process for its preparation. Further, the present invention relates to the use of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-­quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt alone or in combination with other compounds. Further, the present invention relates to formulations of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)­ethyl]-3-(2- methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt in the preparation of pharmaceutical compositions. The invention also relates to the use of such sulfate salts in formulations as neurohormonal antagonists.

Description

ACTELION 66A/U9
1-[2-(4-BENZYL-4-HYDROXY-PIPERIDIN-1-YL)-ETHYL]-3-(2-METHYL- QUINOLIN-4-YL)-UREA AS CRYSTALLINE SULFATE SALT
The present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea as crystalline, stoichiometrically defined and non- hygroscopic sulfate salt and a process for its preparation. Further, the present invention relates to the use of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea as crystalline, stoichiometrically defined and non- hygroscopic sulfate salt alone or in combination with other compounds. The present invention also relates to compositions containing said 1-[2-(4-benzyl- 4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline, stoichiometrically defined and non-hygroscopic sulfate salt and inert carrier material which are useful as urotensin-ll antagonist.
1 -[2-(4-Benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as well as the process for its preparation as free base is known from WO-2004026836. 1 -[2-(4-Benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl- quinolin-4-yl)-urea of formula I has been shown to be a potent urotensin Il receptor antagonist [Marline Clozel et al. in J. Pharmcol. Exp. Ther. 2004, 311 , 204-212].
1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as free base has the disadvantages that it is hygroscopic, its colour changes at higher temperature and higher humidity and it agglomerates to a substance cake under these conditions. Therefore, the said compound of formula I as free base is not suitable as a pharmaceutical product since it is not easy to handle in pharmaceutical preparations. In addition, large scale production and storage of the said compound of formula I causes problems due to the properties mentioned above. An object of the present invention is to provide 1-[2-(4-benzyl-4-hydroxy-piperidin- 1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I in a stoichiometrically defined and non-hygroscopic crystalline form which shows improved properties suitable for a pharmaceutical product, pharmaceutical preparations, production in large scale and storage.
The present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea of formula I as a sulfate trihydrate. A sulfate salt of 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I is described by [Martine Clozel et. al., J Pharmacol Exp Ther. 2004; DOI:10.1124/jpet.104.068320] but no procedure for its preparation has been disclosed.
The present invention also relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as a sulfate dihydrate.
The present invention also relates to a process for preparing 1-[2-(4-benzyl- 4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as stoichiometrically defined and non-hygroscopic sulfate salt which process comprises
a) mixing 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin- 4-yl)-urea of formula I and an organic solvent and adding a solution of sulfuric acid in water, or a solution of sulfuric acid in a mixture of water and an organic solvent, and stirring the mixture; or
b) mixing 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin- 4-yl)-urea of formula I and a mixture of an organic solvent and water and adding a solution of sulfuric acid in water, or a solution of sulfuric acid in a mixture of water and an organic solvent, and stirring the mixture; or
c) adding 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin- 4-yl)-urea of formula I as a solid, or dissolved in a mixture of an organic solvent and water to a solution of sulfuric acid in water or to a solution of sulfuric acid in a mixture of water and an organic solvent, and stirring the mixture; or d) adding 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin- 4-yl)-urea of formula I as a solid, or dissolved in an organic solvent to a solution of sulfuric acid in water or to a solution of sulfuric acid in a mixture of water and an organic solvent, and stirring the mixture; or
e) hydration of a non-defined 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-
3-(2-methyl-quinolin-4-yl)-urea sulfate hydrate by stirring in water, in a mixture of water and an organic solvent, or by exposure to an atmosphere of controlled relative humidity.
According to a preferred embodiment of this process, the sulfate salt of 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I is 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin- 4-yl)-urea sulfate trihydrate.
Further, the present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as stoichiometrically defined and non-hygroscopic sulfate salt obtainable by the process mentioned above.
Further, the present invention relates to pharmaceutical compositions comprising 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as stoichiometrically defined and non-hygroscopic sulfate salt as mentioned above and inert carrier material
Further, the present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as mentioned above and their use as medicaments.
Because of their ability to inhibit the actions of urotensin II, 1-[2-(4-benzyl- 4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as described above can be used for treatment of diseases which are associated with an increase in vasoconstriction, proliferation or other disease states associated with the actions of urotensin II. Examples of such diseases are hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, asthma, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, or pulmonary fibrosis. They can also be used for prevention of restenosis after balloon or stent angioplasty, for the treatment of cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addictions, schizophrenia, Alzheimer's disease, anxiety, obsessive-compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, neurodegenerative diseases, as well as other diseases related to a dysregulation of urotensin Il or urotensin Il receptors.
These compositions may be administered in enteral or oral form e.g. as tablets, dragees, gelatine capsules, emulsions, solutions or suspensions, in nasal form like sprays and aerosols, or rectally in form of suppositories. 1-[2-(4-Benzyl-4-hydroxy- piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as mentioned above may also be administered in intramuscular, parenteral or intravenous form, e.g. in form of injectable solutions.
These pharmaceutical compositions may contain 1-[2-(4-benzyl-4-hydroxy- piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as mentioned above in combination with inorganic and/or organic excipients, which are usual in the pharmaceutical industry, like lactose, maize or derivatives thereof, talcum, stearic acid or salts of these materials.
For gelatine capsules vegetable oils, waxes, fats, liquid or half-liquid polyols etc. may be used. For the preparation of solutions and sirups e.g. water, polyols, saccharose, glucose etc. are used. Injectables are prepared by using e.g. water, polyols, alcohols, glycerin, vegetable oils, lecithin, liposomes etc. Suppositories are prepared by using natural or hydrogenated oils, waxes, fatty acids (fats), liquid or half-liquid polyols etc.
The compositions may contain in addition preservatives, stabilisation improving substances, viscosity improving or regulating substances, solubility improving substances, sweeteners, dyes, taste improving compounds, salts to change the osmotic pressure, buffer, anti-oxidants etc.
1 -[2-(4-Benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as mentioned above may also be used in combination with one or more other therapeutically useful substances e.g. with α- and β-blockers like phentolamine, phenoxybenzamine, atenolol, propranolol, timolol, metoprolol, carteolol, carvedilol, etc.; with vasodilators like hydralazine, minoxidil, diazoxide, flosequinan, etc.; with calcium-antagonists like diltiazem, nicardipine, nimodipine, verapamil, nifedipine, etc.; with angiotensin converting enzyme-inhibitors like cilazapril, captopril, enalapril, lisinopril etc.; with potassium channel activators like pinacidil, chromakalim, etc.; with angiotensin receptor antagonists like losartan, valsartan, candesartan, irbesartan, eprosartan, telmisartan, and tasosartan, etc.; with diuretics like hydrochlorothiazide, chlorothiazide, acetolamide, bumetanide, furosemide, metolazone, chlortalidone, etc.; with sympatholytics like methyldopa, clonidine, guanabenz, reserpine, etc.; with endothelin receptor antagonists like bosentan, clazosentan, tezosentan, darusentan, atrasentan, enrasentan, or sitaxsentan, etc.; with anti-hyperlipidemic agents like lovastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, simvastatin, etc.; and other therapeutics which serve to treat high blood pressure, vascular disease or other disorders listed above.
The dosage may vary within wide limits but should be adapted to the specific situation. In general the dosage given daily in oral form should be between about 3 mg and about 3 g, preferably between about 5 mg and about 1 g, especially preferred between 10 mg and 300 mg, per adult with a body weight of about 70 kg. The dosage should be administered preferably in 1 to 3 doses of equal weight per day. As usual children should receive lower doses which are adapted to body weight and age. The present invention also relates to compositions containing amorphous parts of
1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as mentioned above.
The term "crystallinity" or "crystalline" is used to describe the part of crystalline material compared to amorphous material and is estimated eg. by the line shape and the background intensity in X-ray diffraction patterns.
According to these methods, a crystallinity of 90% to 100% is estimated. In a more preferred embodiment the crystallinity is within the range of 92 % to 100 %. In the most preferred embodiment the crystallinity is within the range of 95 % to 100 %.
The term "organic solvents", as used within the present invention, means solvents or mixtures of solvents, such as Ci-4-alkanol (CH3OH, C2H5OH, n-C3H7OH, 1-C3H7OH, n-C4H9OH, J-C4H9OH, t-C4H9OH), ketones (acetone, ethylmethylketone, methylisobutylketone), ethers (diethylether, tetrahydrofurane, 1 ,4-dioxane, methyl- tert. butylether) or acetonitrile. Preferred "organic solvents" are CH3OH, C2H5OH, n-CsHyOH, J-CaH7OH and acetone. Most preferred "organic solvents" are CH3OH, C2H5OH, J-C3H7OH and acetone.
The term "solution of sulfuric acid" as used within the present invention, means solutions of sulfuric acid in water, or a solution of sulfuric acid in a mixture of water and an organic solvent., preferably aqueous solutions. Sulfuric acid solutions are in the concentration range of 0.01 to 10 mol/L, more preferred in the concentration range of 0.1 to 5 mol/L, most preferred in the concentration range of 0.2 to
2 mol/L.
The term "stoichiometrically defined crystalline form", as used within the present invention, means crystalline compounds as described before that contain 1 [2 (4 benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of Formula I, sulfuric acid and water in a defined molecular ratio X:Y:Z, whereby X and Y represent 1 , and Z represents the numbers 0 to 4. In a more preferred embodiment Z represents the numbers 0 to 3. In the most preferred embodiment Z represents the numbers 2 or 3. The foregoing general description of the invention will now be further illustrated with a number of non-limiting examples.
EXAMPLES ACCORDING TO THE INVENTION LIST OF ABBREVIATIONS:
aq. aqueous
DVS dynamic vapor sorption
HV high vacuum conditions min minutes
RH relative humidity r.t. room temperature
V volume w weight
XRD X-ray powder diffraction
X-ray diffraction patterns (XRD) were recorded on a Bruker D5000, using a Cu- Kaipha (1.5418 A) source, a 4OkV - 3OmA generator, in a range of 3 et 40° (2theta).
DVS is performed as gravimetric measurement (10 - 30 mg of sample), at a given temperature, under controlled relative humidity. Measurements are performed on a
SMS (Surface Measurement Sytems) DVS 1000. First, the sample is dried (0%
RH) under dry nitrogen at the experiment temperature. Then a cycle of relative humidity (RH) is applied to the sample (generally increase by steps e.g. 20, 40, 60 and 80% RH and decrease to 0% RH by the same steps). The duration of each step of RH is sufficient to reach a weight equilibrium.
Example 1
1-r2-(4-Ben2yl-4-hvdroxy-piperidin-1-yl)-ethvn-3-(2-methyl-quinolin-4-yl)-urea sulfate tri hydrate
1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea (1 equivalent) is dissolved in ethanol at a concentration of 25%w/w and the mixture is heated at 5O0C. Aqueous sulfuric acid (1M, 1.1 equivalents) is added. Optionally, the crystallization is initiated by a wet seed of Example 1 (0.5%). The suspension is cooled to 00C with a cooling rate of 15°C/h and maintained at this temperature at least 1 hour before filtration and washing with aqueous ethanol (50 % W/W). The solid is dried at 300C under a wet stream of nitrogen (50% RH) to provide the title compound with a purity of 97.7% with a yield of approximately 90%.
X-ray diffraction pattern (XRD) of 1-r2-(4-benzyl-4-hvdroxy-piperidin- 1-yl)-ethyll-3-(2-methyl-quinolin-4-yl)-urea sulfate tri hydrate described in Example 1
Figure 1 shows the XRD-diffraction pattern of the compound described in Example 1. Table 1 summarizes the peaks and their intensity.
The parameters used to obtain these results were as follows:
Example 1 Type : 2Th/Th locked - Start : 3.000° - End : 40.000° - Step : 0.020° - Step time : 1 s - Temp. : 25°C (room temperature) - Time Started : 3 s - 2-Theta : 3.000° - Theta : 1.500° - Phi : 0.00° DIF - Y : 77.31 % - d x by : 1.- WL : 1.54056 - 0-
Table 1 : 2-Theta Angles and their intensities of the X-ray diffraction pattern (XRD) of the compound described in Example 1
It has to be understood that due to small changes in the experimental details, small deviations in the 2-Theta values of the characteristic peaks in the X-ray powder diffraction patterns may occur.
Crystal structure information of Η2-(4-benzyl-4-hvdroxy-piperidin-1- yl)-ethvπ-3-(2-methyl-quinolin-4-yl)-urea sulfate tri hydrate described in
Example 1:
Formula C25 H38 N4 09 S1
Crystal Class Monoclinic Space Group P 1 21/c 1 a 9.90180(10) alpha 90.02 b 11.62120(10) beta 92.1147(5) c 24.4348(2) gamma 90.02
Coordinates
S1 5 0.61225 0.30855 0.69926 1.00000 0.02322 0.02464 0.02313 0.00167
0.00063 0.00177 02 4 0.75650 0.31402 0.71730 1.00000 0.02586 0.03254 0.02979 0.00278 -
0.00447 0.00256
03 4 0.58955 0.38261 0.65118 1.00000 0.03122 0.04462 0.03211 0.01219 - 0.00409 0.00430
04 4 0.57966 0.18851 0.68588 1.00000 0.03488 0.02929 0.04629 -0.00599 0.00578 -0.00161
05 4 0.52793 0.35026 0.74402 1.00000 0.03548 0.03517 0.03507 -0.00384 0.01084 -0.00025
C6 1 1.06055 0.14970 0.64896 1.00000 0.02454 0.02130 0.02257 0.00206
0.00058 -0.00056 C7 1 1.12232 0.24424 0.61313 1.00000 0.03172 0.02449 0.02891 0.00194
0.00403 -0.00495 C8 1 1.11753 0.21849 0.55275 1.00000 0.02995 0.02402 0.02877 0.00430
0.00426 -0.00571
C9 1 1.21317 0.14730 0.52949 1.00000 0.03226 0.027420.03788 0.00418 0.00723 -0.00204
C10 1 1.20706 0.12488 0.47335 1.00000 0.05040 0.027420.04308 -0.00375
0.01655 -0.00362 C11 1 1.10561 0.17362 0.44020 1.00000 0.05518 0.036890.03007 -0.00216
0.00308 -0.01324 C12 1 1.01004 0.24365 0.46248 1.00000 0.03887 0.039090.03499 0.00696 -
0.00108 -0.00786 C13 1 1.01638 0.26594 0.51861 1.00000 0.03167 0.033850.03080 0.00592
0.00465 -0.00114
C14 1 1.06064 0.19260 0.70839 1.00000 0.02371 0.026750.02450 -0.00049 - 0.00073 -0.00262
C15 1 0.99245 0.10870 0.74596 1.00000 0.02345 0.028990.02040 0.00092 -
0.00158 0.00013 N16 3 0.84909 0.08816 0.72582 1.00000 0.02198 0.022390.02046 0.00057
0.00103 -0.00159 C17 1 0.84692 0.03907 0.66903 1.00000 0.02489 0.026140.02038 -0.00248
0.00158 -0.00282 C18 1 0.91619 0.12027 0.62983 1.00000 0.02443 0.026940.02117 0.00136
0.00007 -0.00088 C19 1 0.77287 0.01423 0.76410 1.00000 0.02965 0.023210.02425 0.00293
0.00416 -0.00174 C20 1 0.72630 0.08309 0.81299 1.00000 0.03694 0.026600.02164 0.00124
0.00755 -0.00374
N21 3 0.65520 0.00988 0.84999 1.00000 0.03150 0.032830.01998 0.00113 0.00270 -0.00819
C22 1 0.70082 -0.00650 0.90231 1.00000 0.02529 0.023560.02126 -0.00087
0.00274 -0.00165 N23 3 0.61239 -0.07503 0.93170 1.00000 0.02335 0.025550.02022 0.00053
0.00116 -0.00338 C24 1 0.62202 -0.09992 0.98648 1.00000 0.02275 0.021730.02082 -0.00006
0.00294 0.00242 C25 1 0.52400 -0.17760 1.00846 1.00000 0.02295 0.023710.02385 0.00080
0.00346 0.00286
C26 1 0.53177 -0.20051 1.06518 1.00000 0.02457 0.025750.02287 0.00108 0.00249 0.00319
N27 3 0.63200 -0.14985 1.09755 1.00000 0.02772 0.031660.01952 0.00063
0.00208 0.00192 C28 1 0.72600 -0.08148 1.07716 1.00000 0.02478 0.030710.02230 -0.00180
0.00144 0.00249 C29 1 0.72175 -0.05396 1.02179 1.00000 0.02536 0.027060.02325 0.00002
0.00233 -0.00077 C30 1 0.83455 -0.03727 1.11567 1.00000 0.03160 0.045950.02380 -0.00433
0.00394 -0.00283
C31 1 0.44021 -0.27599 1.08943 1.00000 0.03315 0.032960.02721 0.00431 0.00675 0.00116
C32 1 0.34335 -0.33018 1.05725 1.00000 0.03354 0.033580.03909 0.00468
0.00903 -0.00618 C33 1 0.33499 -0.30941 1.00057 1.00000 0.03129 0.034720.03698 0.00074
0.00063 -0.00758 C34 1 0.42228 -0.23517 0.97654 1.00000 0.02790 0.029450.02830 0.00056
0.00076 -0.00283
035 4 0.80651 0.03300 0.92140 1.00000 0.03090 0.040630.02968 0.00500 0.00135 -0.01196
036 4 1.13670 0.04565 0.64500 1.00000 0.02594 0.024890.02898 0.00159 0.00165 0.00240
037 4 0.35801 0.20143 0.79365 1.00000 0.04596 0.056900.02594 0.00553 0.00357 -0.01359
038 4 0.62759 0.54632 0.79414 1.00000 0.03006 0.039070.05616 -0.01265 0.00524 0.00291 039 4 0.90339 0.32234 0.81772 1.00000 0.05421 0.028700.04454 -0.00971 0.01512 0.00371
DVS of 1-r2-(4-benzyl-4-hvdroxy-piperidin-1-yl)-ethyl1-3-(2-methyl- quinolin-4-yl)-urea sulfate tri hydrate described in Example 1
Table 2 summarizes the results of two cycles (0 to 85 % relative humidity) in a DVS measurement (4O0C) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate described in Example 1. Table 2: DVS data of the compound described in Example 1
Target Change In Mass (%)
RH (%) Sorption Desorption Hysteresis
Cycle 1 0.0 0.00 -0.02
20.0 9.71 9.97 0.26
40.0 10.23 10.26 0.03
60.0 10.42 10.40 -0.02
85.0 10.68 10.68
Cycle 2 0.0 -0.02 -0.02
20.0 9.81 9.98 0.17
40.0 10.26 10.28 0.02
60.0 10.42 10.42 0.01
85.0 10.68 10.68
Example 2
1-r2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethvn-3-(2-methyl-quinolin-4-yl)-urea sulfate tri hydrate
To a suspension of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2- methyl-quinolin-4-yl)-urea (21.36 kg) in CH3OH (178 L) is added aqueous H2SO4 (6 L, 9.91%) during 10 min. The clear solution is filtered and further aqueous H2SO4 (33.8 L, 1.07 M) is added during 45 min. The solution is cooled to -2°C during 1.5 h and stirred at -5 to -9°C for 1 h. The formed precipitate is filtered, washed with cooled CH3OH (- 5°C, 54 L) and dried under a stream of nitrogen provide 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I sulfate as a non-defined hydrate. A slurry of the so obtained salt in H2O (16.2% w/w) is stirred for 3 days at 25°C. Filtration and drying at 300C under a wet stream of nitrogen (50% RH) provides the title compound. X-rav diffraction pattern (XRD) of 1-r2-(4-benzyl-4-hvdroxy-piperidin- 1-vπ-ethvH-3-(2-methyl-αuinolin-4-yl)-urea sulfate trihvdrate described in Example 2
Figure 2 shows the XRD-diffraction pattern of the compound described in Example 2. Table 3 summarizes the peaks and their intensity.
The parameters used to obtain these results were as follows:
Example 2 Type : 2Th/Th locked - Start : 3.000° - End : 40.000° - Step : 0.020° - Step time : 1 s - Temp. : 30°C - Time Started : 3 s - 2-Theta : 3.000° - Theta : 1.500° - Phi : 0.00° - Aux1 : 0.0 DIF - Y : 77.08 % - d x by : 1.- WL : 1.54056 - 0-
Table 3: 2-Theta Angles and their intensities of the X-ray diffraction pattern (XRD) of the compound described in Example 2
DVS of 1-r2-(4-benzyl-4-hvdroxy-piperidin-1-yl)-ethyll-3-(2-methyl- quinolin-4-yl)-urea sulfate tri hydrate described in Example 2
Table 4 summarizes the results of three cycles (0 to 85 % relative humidity) in a DVS measurement (25°C) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate described in Example 2.
Table 4: DVS data of the compound described in Example 2
Target Change In Mass (%)
RH (%) Sorption Desorption Hysteresis
Cycle 1 0.0 0.00 -0.01
20.0 11.38 11.94 0.57
40.0 12.00 12.31 0.32
60.0 12.41 12.49 0.08
85.0 12.70 12.70
Cycle 2 0.0 -0.01 0.00
20.0 11.52 11.95 0.43
40.0 12.06 12.32 0.25
60.0 12.41 12.49 0.07
85.0 12.70 12.70
Cycle 3 0.0 0.00 0.08
20.0 11.55
40.0 12.07
60.0 12.40
85.0 12.69 12.69
Example 3
1-r2-(4-Benzyl-4-hvdroxy-piperidin-1-yl)-ethvn-3-(2-methyl-quinolin-4-yl)-urea sulfate di hydrate
To a suspension of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2- methyl-quinolin-4-yl)-urea (21.36 kg) in CH3OH (178 L) is added aqueous H2SO4 (6 L, 9.91%) during 10 min. The clear solution is filtered and further aqueous H2SO4 (33.8 L1 1.07 M) is added during 45 min. The solution is cooled to -2°C during 1.5 h and stirred at -5 to -90C for 1 h. The formed precipitate is filtered, washed with cooled CH3OH (- 5°C, 54 L) and dried under a stream of nitrogen provide 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I sulfate as a non-defined hydrate. The so obtained salt is exposed to humid atmosphere (>70 % RH) at 250C to provide the title compound.
X-ray diffraction pattern (XRD) of 1-f2-(4-benzyl-4-hydroxy-piperidin- 1-yl)-ethyll-3-(2-methyl-quinolin-4-yl)-urea sulfate tri hydrate described in Example 3
Figure 3 shows the XRD-diffraction pattern of the compound described in Example 3. Table 5 summarizes the peaks and their intensity.
The parameters used to obtain these results were as follows:
Example 3 Type : 2Th/Th locked - Start : 4.010° - End : 40.010° - Step : 0.020° - Step time : 1 s - Temp. : 250C (room temperature) - Time Started : 0 s - 2-Theta : 4.010° DIF - Y : 79.17 % - d x by : 1.- WL : 1.54056 - 0-
Table 5: 2-Theta Angles and their intensities of the X-ray diffraction pattern (XRD) of the compound described in Example 3
Example 4
1-F2-(4-Benzyl-4-hvdroxy-piperidin-1-yl)-ethvn-3-(2-methyl-quinolin-4-yl)-urea sulfate tri hydrate
1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea (15.4 kg, 1 equivalent) is dissolved in ethanol (78 L) and the mixture is heated at 500C. Aqueous sulfuric acid (1 M, 1.1 equivalents) is added during 35 minutes. The crystallization is initiated by a wet seed of Example 1 (1%) as described below. The suspension is cooled to 1°C with a cooling rate of 14°C/h and maintained at this temperature at least 11 hours before filtration and washing with aqueous ethanol (50 % VWW, 50 L). The solid is dried at 30°C under a wet stream of nitrogen (33-40% RH) to provide the title compound with a purity of 99.4% with a yield of approximately 79%.
The wet seed used in the above procedure is prepared by mixing 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea sulfate trihydrate (Example 1 , 104 g) with a saturated solution (421 g) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea sulfate trihydrate (Example 1 , 73.9 g) in aqueous ethanol (50 % VWW, 81O g).
Example 5
1-r2-(4-Benzyl-4-hvdroxy-piperidin-1-yl)-ethyll-3-(2-methyl-quinolin-4-yl)-urea sulfate trihvdrate
1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea (1.01 kg, 1 equivalent) is dissolved in ethanol (3.05 kg) under stirring (200±20 rpm) and the mixture is heated at 500C. Aqueous sulfuric acid (1 M, 1.1 equivalents) is added during 20 minutes. The crystallization is initiated by a wet seed of Example 1 (1%) as described below. The obtained mixture is maintained at 500C for about 15 minutes, then it is cooled to 00C with a cooling rate of 15°C/h and maintained at this temperature for least 1 hour before filtration and washing with aqueous ethanol (50 % W/W, 3 kg). The solid is dried in a conductive agitated dryer at a temperature of 35±3°C under a wet stream of nitrogen (45+5% RH), optionally under stirring (max. 70 rpm) in case the cake humidity is below 25%, to provide the title compound with a purity of 99.8% with a yield of approximately 94%. The wet seed used in the above procedure is added in two shots and is prepared by mixing 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate (Example 1 , 6.5 g) with a saturated solution (13.9 g for the first shot, plus 15.6 g for subsequent rinsing and second shot) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate (Example 1 , 7.0 g) in aqueous ethanol (50 % W/W, 50.0 g) for about 2 minutes. The first shot of wet seed is prepared at least 5 minutes before use to ensure that the seed is correctly wetted.

Claims

Claims
1. 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea of formula I as sulfate salt in a stoichiometrically defined crystalline form.
2. 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea of formula I, which is a sulfate trihydrate.
3. 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea of formula I1 which is a sulfate dihydrate.
4. 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea of formula I as sulfate salt in crystalline form according to claim 2 having an X-ray powder diffraction pattern as depicted in Figure 1.
5. 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea of formula I as sulfate salt in crystalline form according to claim 2 having an X-ray powder diffraction pattern as depicted in Figure 2.
6. 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea of formula I as sulfate salt in crystalline form according to claim 3 having an X-ray powder diffraction pattern as depicted in Figure 3.
7. 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea of formula I as sulfate salt in crystalline form according to claim 2 which shows the peaks at the diffraction (2-theta) angles shown in Table 1 in its X-ray powder diffraction pattern.
8. 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea of formula I as sulfate salt in crystalline form according to claim 2 which shows the peaks at the diffraction (2-theta) angles shown in Table 3 in its X-ray powder diffraction pattern.
9. 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea of formula I as sulfate salt in crystalline form according to claim 3 which shows the peaks at the diffraction (2-theta) angles shown in Table 5 in its X-ray powder diffraction pattern.
10.1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea of formula I as sulfate salt in crystalline form according to claim 2 having a space group and coordinates as shown below:
Formula C25 H38 N4 09 S1
Crystal Class Monoclinic Space Group P 1 21/c 1 a 9.90180(10) alpha 90.02 b 11.62120(10) beta 92.1147(5) c 24.4348(2) gamma 90.02
Coordinates
S1 5 0.61225 0.30855 0.69926 1.00000 0.02322 0.02464 0.02313 0.00167 0.00063 0.00177
02 4 0.75650 0.31402 0.71730 1.00000 0.02586 0.03254 0.02979 0.00278 - 0.00447 0.00256
03 4 0.58955 0.38261 0.65118 1.00000 0.03122 0.04462 0.03211 0.01219 - 0.00409 0.00430
04 4 0.57966 0.18851 0.68588 1.00000 0.03488 0.02929 0.04629 -0.00599 0.00578 -0.00161 05 4 0.52793 0.35026 0.74402 1.00000 0.03548 0.03517 0.03507 -0.00384
0.01084 -0.00025 C6 1 1.06055 0.14970 0.64896 1.00000 0.02454 0.02130 0.02257 0.00206
0.00058 -0.00056
C7 1 1.12232 0.24424 0.61313 1.00000 0.03172 0.024490.02891 0.00194 0.00403 -0.00495
C8 1 1.11753 0.21849 0.55275 1.00000 0.02995 0.024020.02877 0.00430
0.00426 -0.00571 C9 1 1.21317 0.14730 0.52949 1.00000 0.03226 0.027420.03788 0.00418
0.00723 -0.00204 C10 1 1.20706 0.12488 0.47335 1.00000 0.05040 0.027420.04308 -0.00375
0.01655 -0.00362 C11 1 1.10561 0.17362 0.44020 1.00000 0.05518 0.036890.03007 -0.00216
0.00308 -0.01324
C12 1 1.01004 0.24365 0.46248 1.00000 0.03887 0.039090.03499 0.00696 - 0.00108 -0.00786
C13 1 1.01638 0.26594 0.51861 1.00000 0.03167 0.033850.03080 0.00592
0.00465 -0.00114 C14 1 1.06064 0.19260 0.70839 1.00000 0.02371 0.026750.02450 -0.00049 -
0.00073 -0.00262 C15 1 0.99245 0.10870 0.74596 1.00000 0.02345 0.028990.02040 0.00092 -
0.00158 0.00013 N16 3 0.84909 0.08816 0.72582 1.00000 0.02198 0.022390.02046 0.00057
0.00103 -0.00159
C17 1 0.84692 0.03907 0.66903 1.00000 0.02489 0.026140.02038 -0.00248 0.00158 -0.00282
C18 1 0.91619 0.12027 0.62983 1.00000 0.02443 0.026940.02117 0.00136
0.00007 -0.00088 C19 1 0.77287 0.01423 0.76410 1.00000 0.02965 0.023210.02425 0.00293
0.00416 -0.00174 C20 1 0.72630 0.08309 0.81299 1.00000 0.03694 0.026600.02164 0.00124
0.00755 -0.00374 N21 3 0.65520 0.00988 0.84999 1.00000 0.03150 0.032830.01998 0.00113
0.00270 -0.00819 C22 1 0.70082 -0.00650 0.90231 1.00000 0.02529 0.023560.02126 -0.00087
0.00274 -0.00165 N23 3 0.61239 -0.07503 0.93170 1.00000 0.02335 0.025550.02022 0.00053
0.00116 -0.00338
C24 1 0.62202 -0.09992 0.98648 1.00000 0.02275 0.021730.02082 -0.00006 0.00294 0.00242
C25 1 0.52400 -0.17760 1.00846 1.00000 0.02295 0.023710.02385 0.00080
0.00346 0.00286 C26 1 0.53177 -0.20051 1.06518 1.00000 0.02457 0.025750.02287 0.00108
0.00249 0.00319 N27 3 0.63200 -0.14985 1.09755 1.00000 0.02772 0.031660.01952 0.00063
0.00208 0.00192 C28 1 0.72600 -0.08148 1.07716 1.00000 0.02478 0.030710.02230 -0.00180
0.00144 0.00249
C29 1 0.72175 -0.05396 1.02179 1.00000 0.02536 0.027060.02325 0.00002 0.00233 -0.00077
C30 1 0.83455 -0.03727 1.11567 1.00000 0.03160 0.045950.02380 -0.00433 -
0.00394 -0.00283 C31 1 0.44021 -0.27599 1.08943 1.00000 0.03315 0.032960.02721 0.00431
0.00675 0.00116 C32 1 0.34335 -0.33018 1.05725 1.00000 0.03354 0.033580.03909 0.00468
0.00903 -0.00618 C33 1 0.33499 -0.30941 1.00057 1.00000 0.03129 0.034720.03698 0.00074
0.00063 -0.00758
C34 1 0.42228 -0.23517 0.97654 1.00000 0.02790 0.029450.02830 0.00056 0.00076 -0.00283
035 4 0.80651 0.03300 0.92140 1.00000 0.03090 0.040630.02968 0.00500 0.00135 -0.01196
036 4 1.13670 0.04565 0.64500 1.00000 0.02594 0.024890.02898 0.00159 0.00165 0.00240 037 4 0.35801 0.20143 0.79365 1.00000 0.04596 0.056900.02594 0.00553 0.00357 -0.01359
038 4 0.62759 0.54632 0.79414 1.00000 0.03006 0.039070.05616 -0.01265 - 0.00524 0.00291
039 4 0.90339 0.32234 0.81772 1.00000 0.05421 0.028700.04454 -0.00971 - 0.01512 0.00371
11. The process for the preparation of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as sulfate salt according to any one of claims 1 to 10 which process comprises
a. mixing 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl- quinolin-4-yl)-urea of formula I and an organic solvent and adding a solution of sulfuric acid in water, or a solution of sulfuric acid in a mixture of water and an organic solvent, and stirring the mixture; or
b. mixing 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl- quinolin-4-yl)-urea of formula I and a mixture of an organic solvent and water and adding a solution of sulfuric acid in water, or a solution of sulfuric acid in a mixture of water and an organic solvent.and stirring the mixture; or
c. adding 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl- quinolin-4-yl)-urea of formula I as a solid, or dissolved in a mixture of an organic solvent and water to a solution of sulfuric acid in water or to a solution of sulfuric acid in a mixture of water and an organic solvent, and stirring the mixture; or
d. adding 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl- quinolin-4-yl)-urea of formula I as a solid, or dissolved in an organic solvent to a solution of sulfuric acid in water or to a solution of sulfuric acid in a mixture of water and an organic solvent, and stirring the mixture; or
e. hydration of a non-defined 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate hydrate by stirring in water, in a mixture of water and an organic solvent, or by exposure to an atmosphere of controlled relative humidity.
12.1 -[2-(4-Benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea of formula I as sulfate salt obtainable by the process according to claim 11.
13. Compositions comprising 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3- (2-methyl-quinolin-4-yl)-urea of formula I as sulfate salt according to any one of claims 1 to 10 or 12 and inert carrier material.
14. Pharmaceutical compositions containing a compound of any one of claims 1 to 10 or 12 and usual carrier materials and adjuvants for the treatment of disorders which are associated with a dysregulation of urotensin Il or urotensin Il receptors, or disorders associated with vascular or myocardial dysfunction, comprising hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, asthma, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, or pulmonary fibrosis.
15. Pharmaceutical compositions containing a compound of any one of claims 1 to 10 or 12 and usual carrier materials and adjuvants for the treatment of disorders comprising restenosis after balloon or stent angioplasty, for treatment of cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addictions, schizophrenia, Alzheimer's disease, anxiety, obsessive- compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, or neurodegenerative diseases.
16. The use of one or more compounds of any one of claims 1 to 10 or 12 to 13 in combination with other pharmacologically active compounds for the treatment of hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, asthma, chronic obstructive pulmonary disease, high- altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, or pulmonary fibrosis, restenosis after balloon or stent angioplasty, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addiction, schizophrenia, Alzheimer's disease, anxiety, obsessive-compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, or neurodegenerative diseases.
17. The use of one or more compounds of any one of claims 1 to 10 or 12 to 13 in combination with other pharmacologically active compounds comprising ACE inhibitors, angiotensin Il receptor antagonists, endothelin receptor antagonists, vasopressin antagonists, beta-adrenergic antagonists, alpha- adrenergic antagonists, vasopressin antagonists, TNFalpha antagonists, or peroxisome proliferator activator receptor modulators.
18. The method of treating a patient suffering from a disorder given in any one of claims 14 to 16 by administering a pharmaceutical composition according to any one of claims 13 to 15.
19. Compositions containing crystalline parts of 1-[2-(4-benzyl-4-hydroxy- piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as sulfate salt according to any one of claims 1 to 10 and amorphous parts of 1-[2-(4- benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as sulfate salt according to any one of claims 1 to 10, to sum up to
100%.
EP05792250A 2004-10-12 2005-10-11 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt Withdrawn EP1802604A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05792250A EP1802604A1 (en) 2004-10-12 2005-10-11 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2004011410 2004-10-12
PCT/IB2005/053340 WO2006040728A1 (en) 2004-10-12 2005-10-11 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt
EP05792250A EP1802604A1 (en) 2004-10-12 2005-10-11 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt

Publications (1)

Publication Number Publication Date
EP1802604A1 true EP1802604A1 (en) 2007-07-04

Family

ID=38115910

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05792250A Withdrawn EP1802604A1 (en) 2004-10-12 2005-10-11 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt

Country Status (1)

Country Link
EP (1) EP1802604A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079552A1 (en) * 2004-10-12 2006-04-13 Jorg Velker 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079552A1 (en) * 2004-10-12 2006-04-13 Jorg Velker 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salt

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006040728A1 *

Similar Documents

Publication Publication Date Title
TWI418553B (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester-methanesulfonate and its use as a medicament
CA2614334C (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
OA13248A (en) Benzimidazolone coumpounds having 5-HT4 receptor agonistic activity.
JP2013532164A (en) Methods for preparing thrombin specific inhibitors
EP3430004B1 (en) Solid state forms of nilotinib salts
US20130197034A1 (en) Salts Of Methyl 2-((R)-(3-Chlorophenyl)((R)-1-((S)-2-(Methylamino)-3-((R)-Tetrahydro-2H-Pyran-3-Yl)Propylcarbamoyl)Piperidin-3-Yl)Methoxy)Ethylcarbamate
JP5564147B2 (en) New benzamide derivatives
US8067601B2 (en) 1-[2-(4-benzyl-4-hydroxy-piperidin-1 -yl )-ethyl]-3-(2-methyl-quinolin- 4-yl)- urea as crystalline sulfate salt
WO2012090221A1 (en) Novel salts of imatinib
EP1802604A1 (en) 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt
JP2020517674A (en) Method for producing vortioxetine HBr α form
NZ576241A (en) Crystalline forms of -3-(1H-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-dione acetate
US20060122233A1 (en) Rabeprazole calcium
US20060079552A1 (en) 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salt
KR101865868B1 (en) Process for large scale production of 1-isopropyl-3-[5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl]-1h-indazole oxalate
JP2006111531A (en) 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salt
KR20240110861A (en) Compounds used as kinase inhibitors and their uses
CA2484473A1 (en) 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salt
JPWO2004089933A1 (en) New crystals of fluorobenzamide derivatives
KR20060032276A (en) 1-[2- (4-benzyl-4-hydroxy-piperidine-1-yl)-ethyl] -3-(2-methyl-quinolin-4-yl)-urea salt

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070514

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090115

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150520

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151001